KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Evolent Health (EVH) EBIT (2016 - 2026)

Evolent Health has reported EBIT over the past 11 years, most recently at -$408.2 million for Q4 2025.

  • For Q4 2025, EBIT fell 2095.26% year-over-year to -$408.2 million; the TTM value through Dec 2025 reached -$410.1 million, down 913.06%, while the annual FY2025 figure was -$410.1 million, 913.06% down from the prior year.
  • EBIT for Q4 2025 was -$408.2 million at Evolent Health, down from $886000.0 in the prior quarter.
  • Over five years, EBIT peaked at $13.0 million in Q3 2022 and troughed at -$408.2 million in Q4 2025.
  • A 5-year average of -$28.0 million and a median of -$9.0 million in 2021 define the central range for EBIT.
  • Biggest five-year swings in EBIT: surged 296.79% in 2022 and later tumbled 2095.26% in 2025.
  • Year by year, EBIT stood at -$12.2 million in 2021, then skyrocketed by 84.62% to -$1.9 million in 2022, then tumbled by 1036.85% to -$21.3 million in 2023, then grew by 12.9% to -$18.6 million in 2024, then tumbled by 2095.26% to -$408.2 million in 2025.
  • Business Quant data shows EBIT for EVH at -$408.2 million in Q4 2025, $886000.0 in Q3 2025, and -$1.2 million in Q2 2025.